ReviewFrontiers in immunology2016
Regulatory Functions of Natural Killer Cells in Multiple Sclerosis.
Review in Frontiers in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility.Journal of neurology · 2022Pooled it
- Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial.Annals of the rheumatic diseases · 2020Trial
- Adaptive Features of Natural Killer Cells in Multiple Sclerosis.Frontiers in immunology · 2019Trial
- Natural Killer Cells: Dual Regulators and Therapeutic Targets in Multiple Sclerosis Immunopathogenesis.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026Review
- Immunomodulatory effects of medicinal and edible plants in autoimmune diseases: mechanisms and therapeutic potential.Frontiers in immunology · 2026Review
- Immunomodulatory and anti-inflammatory potential of S-nitrosoglutathione (GSNO) in multiple sclerosis: a review of mechanisms and therapeutic perspectives.Frontiers in immunology · 2026Review
- The physiological and pathological effects of sphingolipid metabolism and signaling in the central nervous system.Brain pathology (Zurich, Switzerland) · 2026Review
- Natural Killer Cells in Graves' Disease: Increased Frequency but Impaired Degranulation Ability Compared to Healthy Controls.International journal of molecular sciences · 2025Article
- Effect of Fingolimod on Lymphocyte Subsets in Patients With Relapsing Multiple Sclerosis.Cureus · 2024Article
- CNS Resident Innate Immune Cells: Guardians of CNS Homeostasis.International journal of molecular sciences · 2024Review
- Relapsing-remitting multiple sclerosis patients exhibit differential natural killer functional subpopulations.Acta neurologica Belgica · 2024Article
- NK Cell Levels Correlate with Disease Activity in Patients with Multiple Sclerosis on Ocrelizumab/Rituximab Therapy.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Article
- Regulatory NK cells in autoimmune disease.Iranian journal of basic medical sciences · 2023Review
- Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy.Neurology(R) neuroimmunology & neuroinflammation · 2023Article
- Mass cytometry reveals cladribine-induced resets among innate lymphoid cells in multiple sclerosis.Scientific reports · 2022Article
- Temporal Expression of Transcription FactorACS synthetic biology · 2022Article
- Herpesvirus Infections in KIR2DL2-Positive Multiple Sclerosis Patients: Mechanisms Triggering Autoimmunity.Microorganisms · 2022Article
- Natural Killer Cells in Multiple Sclerosis: Entering the Stage.Frontiers in immunology · 2022Review
- Innate Lymphoid Cells - Neglected Players in Multiple Sclerosis.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is increasing evidence that natural killer (NK) cells exhibit regulatory features. Among them, CD56
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.